Stock BEACONPHAR BEACON PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beacon Pharmaceuticals PLC

Equities

BEACONPHAR

BD0482BECON5

Pharmaceuticals

End-of-day quote Dhaka S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
189.9 BDT -2.96% Intraday chart for Beacon Pharmaceuticals PLC -5.57% -22.49%
Feb. 13 Beacon Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Jan. 30 Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary CI

Valuation

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Capitalization 1 4,112 4,643 14,022 28,552 59,667 56,595
Enterprise Value (EV) 1 5,462 6,132 15,590 30,705 62,950 63,573
P/E ratio 32.6 x 39.4 x 36.8 x 33.1 x 63.8 x 111 x
Yield 3.37% 2.49% - 1.21% 0.62% 0.65%
Capitalization / Revenue 1.09 x 1 x 2.51 x 4.01 x 7.44 x 6.65 x
EV / Revenue 1.45 x 1.32 x 2.79 x 4.31 x 7.85 x 7.47 x
EV / EBITDA 7.2 x 7.1 x 18.5 x 17.6 x 30.6 x 42.8 x
EV / FCF -146 x -367 x -67.9 x -54.6 x -54.9 x -18.2 x
FCF Yield -0.69% -0.27% -1.47% -1.83% -1.82% -5.5%
Price to Book 1.37 x 1.56 x 3.03 x 5.33 x 10 x 9.52 x
Nbr of stocks (in thousands) 231,000 231,000 231,000 231,000 231,000 231,000
Reference price 2 17.80 20.10 60.70 123.6 258.3 245.0
Announcement Date 11/15/18 11/27/19 12/20/21 12/20/21 11/22/22 12/5/23
1BDT in Million2BDT
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Net sales 1 3,761 4,647 5,591 7,121 8,023 8,510
EBITDA 1 758.7 863.4 844.5 1,747 2,057 1,487
EBIT 1 263.3 314.4 333.5 1,362 1,617 967.7
Operating Margin 7% 6.77% 5.96% 19.12% 20.16% 11.37%
Earnings before Tax (EBT) 1 126 163.4 184.5 1,198 1,293 679.1
Net income 1 126.1 117.7 380.7 863.2 935 509.8
Net margin 3.35% 2.53% 6.81% 12.12% 11.65% 5.99%
EPS 2 0.5459 0.5095 1.648 3.737 4.048 2.207
Free Cash Flow 1 -37.47 -16.71 -229.6 -562 -1,146 -3,498
FCF margin -1% -0.36% -4.11% -7.89% -14.28% -41.1%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.6000 0.5000 - 1.500 1.600 1.600
Announcement Date 11/15/18 11/27/19 12/20/21 12/20/21 11/22/22 12/5/23
1BDT in Million2BDT
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net Debt 1 1,350 1,488 1,568 2,153 3,282 6,978
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.779 x 1.724 x 1.857 x 1.233 x 1.596 x 4.694 x
Free Cash Flow 1 -37.5 -16.7 -230 -562 -1,146 -3,498
ROE (net income / shareholders' equity) 4.21% 3.94% 10% 17.3% 16.6% 8.58%
ROA (Net income/ Total Assets) 3.29% 4.02% 3.46% 10.8% 10.4% 4.75%
Assets 1 3,837 2,929 11,003 7,968 8,951 10,730
Book Value Per Share 2 13.00 12.90 20.00 23.20 25.70 25.70
Cash Flow per Share 2 0.3700 1.220 2.590 1.460 2.330 1.960
Capex 1 324 244 314 313 1,719 1,814
Capex / Sales 8.61% 5.24% 5.62% 4.4% 21.43% 21.32%
Announcement Date 11/15/18 11/27/19 12/20/21 12/20/21 11/22/22 12/5/23
1BDT in Million2BDT
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
BEACON PHARMACEUTICALS PLC Stock Beacon Pharmaceuticals PLC
-22.49% 400M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BEACONPHAR Stock
  4. Financials Beacon Pharmaceuticals PLC